Eli Lilly launches once-a-week diabetes drug, Trulicity in India
Advertisement
New Delhi: In a move to enhance its diabetes portfolio in India, US pharma major Eli Lilly has launched once-a-week diabetes treatment drug under the brand name 'Trulicity', at Rs 2,499 in the country.
The company has launched the product after receiving the regulatory approval for the same in India.
"We are pleased to be introducing Trulicity, first, once-a-week diabetes medicine, in India. We have been committed to diabetes for more than 90 years. We are bringing a new medication to India with a proven efficacy," Eli Lilly India Managing Director Edgard Olaizola told PTI.
"The medicine is an injectable medication and belongs to a class called GLP-1 receptor agonists. It is not a insulin," he added.
Trulicity comes in a single-dose pen and is designed to improve the blood sugar control in adults with Type 2 diabetes.
"India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said.
The company has launched the product after receiving the regulatory approval for the same in India.
"We are pleased to be introducing Trulicity, first, once-a-week diabetes medicine, in India. We have been committed to diabetes for more than 90 years. We are bringing a new medication to India with a proven efficacy," Eli Lilly India Managing Director Edgard Olaizola told PTI.
"The medicine is an injectable medication and belongs to a class called GLP-1 receptor agonists. It is not a insulin," he added.
Trulicity comes in a single-dose pen and is designed to improve the blood sugar control in adults with Type 2 diabetes.
"India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.